Peng Xu

Peng Xu

Auto-generated profile, based on publicly available information

Peng Xu

School of Basic Medical Sciences, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education, Xi’an Jiaotong University, Xi’an 710061, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
YXYuxiu Xie
Yuxiu Xie
PXPeng Xu
Peng Xu
KLKang Liu
Kang Liu
SLShuai Lin
Shuai Lin
MWMeng Wang
Meng Wang
HGHui Guo
Hui Guo

22 January 2020 in Aging
Verified
Journal Article
Open access
YXYuxiu Xie
Yuxiu Xie
PXPeng Xu
Peng Xu
MWMeng Wang
Meng Wang
YZYi Zheng
Yi Zheng
TTTian Tian
Tian Tian
ZDZhijun Dai
Zhijun Dai
Several studies have indicated that the use of antihypertensive medications may influence the incidence of bladder/kidney cancer, with some scholars refuting any such association. Hence, a systematic review is needed to verify this linkage. we comprehensively searched PubMed, Embase, Web of Science, and the Cochrane Library for original studies reporting a relationship between antihypertensive medications and risk of bladder/kidney cancer. We included 31 articles comprising 3,352,264 participants. We found a significant association between the risk of kidney cancer and any antihypertensive medications use (relative risk (RR) = 1.45, 95% CI 1.20-1.75), as well as angiotensin-converting enzyme inhibitors (RR = 1.24, 95% CI 1.04-1.48), angiotensin II receptor blockers (ARB) (RR = 1.29, 95% CI:1.22-1.37), beta-blockers (RR = 1.36, 95% CI 1.11-1.66), calcium-channel blockers (RR = 1.65, 95% CI 1.54-1.78) and diuretics (RR = 1.34, 95% CI 1.19-1.51). In case of bladder cancer, a statistical significance was observed with the use of ARB (RR = 1.07, 95% CI 1.03-1.11) but not with the other antihypertensive medications. There was a linear association between the duration of antihypertensive medications and the risk of kidney cancer (P = 0.061 for a non-linear trend) and the pooled RR for the per year increase in antihypertensive medications duration of use was 1.02 (95% CI: 1.01-1.02). Our results indicate that there is a significant association between each class of antihypertensive medications and the risk of kidney cancer, and this trend presented as a positive linear association. Furthermore, the use of ARB has been linked to the risk of bladder cancer.

1 April 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
PXPeng Xu
Peng Xu
JYJia Yao
Jia Yao
ZLZhen Li
Zhen Li
MWMeng Wang
Meng Wang
LZLinghui Zhou
Linghui Zhou
ZDZhijun Dai
Zhijun Dai
Introduction: Sonodynamic Therapy (SDT) has good targeting and non-invasive advantages in solid cancers, but its antitumor effect is not sufficient to replace traditional treatments. Some studies that combined SDT with chemotherapy or nanoparticles have managed to enhance its efficiency and overcome the side effects of chemotherapy. Materials and Methods: In this study, we synthesized and characterized mesoporous silica nanoparticles (MSN-DOX-Ce6) loaded with doxorubicin (DOX) and sonosensitizer, chlorin e6 (Ce6). Then, we conducted in vitro and in vivo experiments to explore the antitumor effect of MSN-DOX-Ce6 under ultrasound (US) treatment. Results: The characterization tests showed that the nanoparticles are uniformly sized spheres with mesoporous structure, resulting in a high drug-loading efficiency. In the in vitro experiments, MSN-DOX-Ce6 could effectively inhibit cell proliferation under US but not more than other treatment groups. However, the in vivo studies showed that MSN-DOX-Ce6+US has better antitumor effect than DOX+Ce6+US or DOX alone on xenograft tumor-bearing mice. Conclusion: In summary, MSNs showed a great potential for DOX and Ce6 delivery. We concluded that under US, MSN-DOX-Ce6 nanocomposites increase the antitumor effect of DOX and SDT and thereby are a potential treatment for solid tumors.

14 October 2022 in Biomaterials
Verified
Journal Article
Closed access
HLHongwei Lu
Hongwei Lu
JXJi Xu
Ji Xu
JYJinfan Yang
Jinfan Yang
ZWZhongling Wang
Zhongling Wang
PXPeng Xu
Peng Xu
PLPeiyuan Li
Peiyuan Li

14 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
CSChang Sun
Chang Sun
SWSHUBIN WANG
SHUBIN WANG
WYWenjing Ye
Wenjing Ye
RWRanLin Wang
RanLin Wang
MTMingyu Tan
Mingyu Tan
Shun LuShun Lu
Shun Lu
Objective: This study aimed to investigate the relationship between prognostic and tumor parameters of cervical cancer patients, such as tumor size (TS), tumor volume (TV), and tumor volume reduction rate (TVRR) after external beam radiotherapy.Methods: A total of 217 patients with advanced cervical cancer, classified as Federation of Gynecology and Obstetrics (FIGO) IIa–IVa, were enrolled in the study. Pre- and mid-RT pelvic magnetic resonance imaging (MRI) were performed twice, during RT and just before brachytherapy.Results: The median follow-up time was 51 months (range, 7–111 months). The 5-year overall survival (OS), progression-free survival (PFS), and local failure-free survival (LFFS) rates were 81.3, 85.1, and 92.9%, respectively. Multivariate analysis revealed that tumor parameters including FIGO stage >II (Hazard Ratio, 2.377 and 95% confidence interval [CI], 1.091–5.182; P = 0.029), pre-RT TV >61.6 cm3 (HR, 0.417 and 95% CI, 0.188–0.926; P = 0.032), and mid-RT TV >11.38 cm3 (HR, 3.192 and 95% CI, 1.094–9.316; P = 0.034) were observably associated with OS. Univariate analysis showed that the tumor volume reduction rate (TVRR) was dramatically associated with overall survival (HR, 0.204 and 95% CI 0.033–1.282; P <0.001) and local failure-free survival (P = 0.050).Conclusions: In this retrospective study, TVRR and mid-radiotherapy tumor volume are independent and strong prognostic parameters for patients with local advanced cervical cancer receiving CCRT.

12 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YZYang Zhao
Yang Zhao
PXPeng Xu
Peng Xu
HKHuafeng Kang
Huafeng Kang
SLShuai Lin
Shuai Lin
MWMeng Wang
Meng Wang
ZDZhijun Dai
Zhijun Dai
Prognostic nutritional index as a prognostic biomarker for survival in digestive system carcinomas Prognostic nutritional index as a prognostic biomarker for survival in digestive system carcinomas